Merck and its German cousin spar over branding; Turing kicks off ketamine trial;

@FierceBiotech: Johns Hopkins flags another possible successor to 'Special K' for depression. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Did I say the eteplirsen data was messy? More from the FDA (PDF) | Follow @JohnCFierce

@DamianFierce: $MRK is mad about Merck, KGaA, Darmstadt, Germany, Earth's rebrand. More (PDF) | Follow @DamianFierce

> Merck KGaA's recent branding overhaul is leading to confusion in the U.S., according to Merck ($MRK), which filed a lawsuit challenging its distant relative's marketing practices. More

> Turing Pharmaceuticals, under new management after founder Martin Shkreli's arrest, has begun clinical trials on an intranasal formulation of ketamine designed to treat suicidal thoughts. News

> Pfizer ($PFE) signed a deal with the nonprofit California Institute for Biomedical Research to work together on antibody treatments for heart failure. Item

Medical Device News

@FierceMedDev: FDA makes increasing use of 'real-world' device data a strategic priority. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Heartware shares plunge on bad new about device trial. Article | Follow @VarunSaxena2

@EmilyWFierce: NIH urged to 'break taboo' against using its power to bypass drug patents. FiercePharma article | Follow @EmilyWFierce

> JPM: St. Jude plagued by gap in its portfolio of pacemakers and implantable defibrillators. Story

> NIH commits $313M over four years to sequencing genomics of human disease. Article

> Devices grab $2.7B in VC again, but that may weaken in 2016. Editor's corner

Pharma News

@FiercePharma: Dechra's growth spurt continues with $6M acquisition of Mexican manufacturer. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Huge consumer med capacity coming online for Bayer in China as the economy tanks. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: $GSK vaccines head Slaoui says the company's vax and pharma businesses need each other--aka, no break-up, please | Follow @CarlyHFierce

> It's Merck vs. Merck as name cofusion, complicated by social media, leads to legal showdown. More

> Akorn estimates it overstated '14 financials by $35M. Item

> Merck reaches $830M settlement in long-running Vioxx litigation. Article